Bortezomib-Pomalidomide-Dexamethasone (VPD) As Novel Induction Therapy in Newly-Diagnosed Multiple Myeloma: Early Safety Data from an Ongoing Single Arm Phase-II Investigator-Initiated Clinical Trial (PRIME Study)

Vivek S Radhakrishnan,Naveed Tamboli, Shreya Das,Jeevan Kumar Garg,Arijit Nag,Saurabh J Bhave,Mayur Parihar,Sushant Vinarkar,Sumit Mukhopadhyay,Subhosmito Chakraborty,Deepak K Mishra,Reena Nair,Mammen Chandy

Blood（2021）

引用 1|浏览6

暂无评分

摘要

Introduction: Pomalidomide is a third-generation immunomodulatory drug approved for relapsed and/or refractory Multiple Myeloma (RRMM). In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone demonstrated superior efficacy in patients with RRMM. PRIME study (CTRI/2019/10/021618) is testing this combination in Newly Diagnosed Multiple Myeloma (NDMM)

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要